金斯瑞成功开发并验证了靶向不同免疫细胞（NK细胞、T细胞、巨噬细胞）和补体系统的抗体药物活性鉴定与评价方法和技术，包括ADCC、CDC、ADCP、Phagocytosis、T细胞增激活与抑制分析等，涉及的靶点包括CD20、 EGFR、HER2、tm-TNFa、PD-1/PD-L1、CTLA-4、OX-40、TIM-3、 LAG-3、CD40、4-1BB、B7-H3、TIGIT、GITR及CD47等。
登录
NK细胞 |
T细胞 |
巨噬细胞 |
补体系统 |
|
|---|---|---|---|---|
作用机理 |
Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) |
T cell Activation/Inhibition |
Antibody-Dependent Cellular Phagocytosis (ADCP), Phagocytosis |
Complement Dependent Cytotoxicity (CDC) |
已开发的靶点 |
CD20, EGFR, HER2, tm-TNFa |
PD-1/PD-L1, CTLA-4,OX-40，TIGIT NEW，LAG3 NEW，GITR NEW，4-1BB NEW，CD40 NEW |
CD20, HER2, CD47 |
CD20, tm-TNFa |
方法学 |
PBMC, NK cells, Engineered NK cells, IL-2 release |
Mixed-Lymphocyte Reaction (MLR), Reporter gene assays |
FACS |
Cell lysis detection |
同时，我们开发了Immuno-Oncology相关靶点过表达稳定细胞株库，主要用于细胞免疫、亲和力分析、交叉反应及功能分析等。
| Developed Immuno-Oncology Cell Lines | |||
|---|---|---|---|
Target |
Cell Line |
Target |
Cell Line |
4-1BB |
CHO-K1/human 4-1BB | PD-1 |
CHO-K1/human PD-1 |
| CHO-K1/mouse 4-1BB | CHO-K1/mouse PD-1 | ||
| CHO-K1/cyno 4-1BB | CHO-K1/cyno PD-1 | ||
B7-H3 |
CHO-K1/human B7-H3 | PD-L1 |
CHO-K1/human PD-L1 |
B7-H4 |
CHO-K1/human B7-H4 | HEK293/human PD-L1 | |
BTLA |
CHO-K1/human BTLA | CHO-K1/mouse PD-L1 | |
CD160 |
CHO-K1/human CD160 | CHO-K1/cyno PD-L1 | |
CD200 R1 |
CHO-K1/human CD200 R1 | TIGIT |
CHO-K1/human TIGIT |
CD40 |
CHO-K1/human CD40 | Tim3 |
CHO-K1/human Tim3 |
CD80 |
CHO-K1/human CD80 | VISTA |
CHO-K1/human VISTA |
CD86 |
CHO-K1/human CD86 | FLT3 |
CHO-K1/human FLT3 |
CTLA4 |
CHO-K1/human CTLA4 | CHO-K1/human FLT3 mutant | |
| CHO-K1/mouse CTLA4 | CHO-K1/mouse FLT3 | ||
| CHO-K1/cyno CTLA4 | CHO-K1/cyno FLT3 | ||
GITR |
CHO-K1/human GITR | CD38 |
CHO-K1/human CD38 |
Lag3 |
CHO-K1/human Lag3 | CD27 |
CHO-K1/human CD27 |
OX-40L |
CHO-K1/human OX-40L | OX-40 |
CHO-K1/human OX-40 |
mTNFα |
CHO-DG44/mTNFα | ||
| Jurkat/mTNFα | |||
最新优惠
为了能够高效而准确提供报价，请首先下载并完成询价咨询表，然后填写完整的询价表通过邮件发送给我们，我们将在第一时间内给您答复。
